Cao L, Zhou Y, Gale R, Qin Y, Wu L, Zhao M
Biomol Biomed. 2023; 23(6):1079-1088.
PMID: 37183704
PMC: 10655882.
DOI: 10.17305/bb.2023.9034.
Gao Q, Liu Y, Aypar U, Baik J, Londono D, Sun X
Cytometry B Clin Cytom. 2023; 104(4):279-293.
PMID: 36999235
PMC: 10508218.
DOI: 10.1002/cyto.b.22120.
Modvig S, Hallbook H, Madsen H, Siitonen S, Rosthoj S, Tierens A
Leukemia. 2020; 35(7):1894-1906.
PMID: 33318611
PMC: 8257490.
DOI: 10.1038/s41375-020-01100-5.
Abou Dalle I, Jabbour E, Short N
Ther Adv Hematol. 2020; 11:2040620720910023.
PMID: 32215194
PMC: 7065280.
DOI: 10.1177/2040620720910023.
Rastogi P, Sachdeva M
Indian J Hematol Blood Transfus. 2020; 36(1):3-15.
PMID: 32174688
PMC: 7042470.
DOI: 10.1007/s12288-019-01118-5.
When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.
Lamble A, Phelan R, Burke M
J Clin Med. 2017; 6(7).
PMID: 28686179
PMC: 5532574.
DOI: 10.3390/jcm6070066.
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
Berry D, Zhou S, Higley H, Mukundan L, Fu S, Reaman G
JAMA Oncol. 2017; 3(7):e170580.
PMID: 28494052
PMC: 5824235.
DOI: 10.1001/jamaoncol.2017.0580.
Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.
Sala Torra O, Othus M, Williamson D, Wood B, Kirsch I, Robins H
Biol Blood Marrow Transplant. 2017; 23(4):691-696.
PMID: 28062215
PMC: 5465962.
DOI: 10.1016/j.bbmt.2016.12.639.
Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
Rocha J, Xavier S, Souza M, Assumpcao J, Murao M, de Oliveira B
Mediterr J Hematol Infect Dis. 2016; 8(1):e2016024.
PMID: 27158437
PMC: 4848021.
DOI: 10.4084/MJHID.2016.024.
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
Karawajew L, Dworzak M, Ratei R, Rhein P, Gaipa G, Buldini B
Haematologica. 2015; 100(7):935-44.
PMID: 26001791
PMC: 4486228.
DOI: 10.3324/haematol.2014.116707.
Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.
Salari F, Shahjahani M, Shahrabi S, Saki N
Med Oncol. 2014; 31(11):266.
PMID: 25287907
DOI: 10.1007/s12032-014-0266-3.
Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.
Bar M, Wood B, Radich J, Doney K, Woolfrey A, Delaney C
Leuk Res Treatment. 2014; 2014:421723.
PMID: 24778882
PMC: 3981457.
DOI: 10.1155/2014/421723.
Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan A, Vashi N, Faham M, Carlton V, Kong K, Buno I
Biol Blood Marrow Transplant. 2014; 20(9):1307-13.
PMID: 24769317
PMC: 5259557.
DOI: 10.1016/j.bbmt.2014.04.018.
Genes related to antiviral activity, cell migration, and lysis are differentially expressed in CD4(+) T cells in human t cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.
Pinto M, Malta T, Rodrigues E, Pinheiro D, Panepucci R, Malmegrim de Farias K
AIDS Res Hum Retroviruses. 2013; 30(6):610-22.
PMID: 24041428
PMC: 4046198.
DOI: 10.1089/aid.2013.0109.
Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia.
Weng X, Shen Y, Sheng Y, Chen B, Wang J, Li J
Blood Cancer J. 2013; 3:e133.
PMID: 23955588
PMC: 3763385.
DOI: 10.1038/bcj.2013.31.
Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.
Gaipa G, Cazzaniga G, Valsecchi M, Panzer-Grumayer R, Buldini B, Silvestri D
Haematologica. 2012; 97(10):1582-93.
PMID: 22581001
PMC: 3487561.
DOI: 10.3324/haematol.2011.060426.
Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
Obro N, Ryder L, Madsen H, Andersen M, Lausen B, Hasle H
Haematologica. 2011; 97(1):137-41.
PMID: 21933850
PMC: 3248943.
DOI: 10.3324/haematol.2011.051383.
Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.
Elorza I, Palacio C, Dapena J, Gallur L, Sanchez de Toledo J, Diaz de Heredia C
Haematologica. 2010; 95(6):936-41.
PMID: 20179088
PMC: 2878791.
DOI: 10.3324/haematol.2009.010843.
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.
Bene M, Kaeda J
Haematologica. 2009; 94(8):1135-50.
PMID: 19586938
PMC: 2719036.
DOI: 10.3324/haematol.2008.004267.
A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli C, Assumpcao J, Ganazza M, Araujo M, Toledo S, Lee M
Haematologica. 2009; 94(6):781-9.
PMID: 19483156
PMC: 2688569.
DOI: 10.3324/haematol.2008.003137.